Structure Based Multitargeted Molecular Docking Analysis of Selected Furanocoumarins against Breast Cancer
Структурно-ориентированный мультитаргетный анализ молекулярного докинга выбранных фуранокумаринов против рака молочной железы
2019-10-31
SCID: 54.1/v2sasxs4
Discuss with AI
ERα, PR, EGFR and mTORLipinski's rule of fivebreast cancerfuranocoumarinsmultitargeted molecular docking
Figures from the paper
Abstract (AI)
Breast cancer is one of the biggest global dilemmas and its current therapy is to target the hormone receptors by the use of partial agonists/antagonists. Potent drugs for breast cancer treatment are Tamoxifen, Trastuzumab, Paclitaxel, etc. which show adverse effects and resistance in patients. The aim of the study has been on certain phytochemicals which has potent actions on ERα, PR, EGFR and mTOR inhibition. The current study is performed by the use of molecular docking as protein-ligand interactions play a vital role in drug design. The 3D structures of ERα, PR, EGFR and mTOR were obtained from the protein data bank and docked with 23 3D PubChem structures of furanocoumarin compounds using FlexX. Drug-likeness property was checked by applying the Lipinski's rule of five on the furanocoumarins to evaluate anti-breast cancer activity. Antagonist and inhibition assay of ERα, EGFR and mTOR respectively has been performed using appropriate in-vitro techniques. The results confirm that Xanthotoxol has the best docking score for breast cancer followed by Bergapten, Angelicin, Psoralen and Isoimperatorin. Further, the in-vitro results also validate the molecular docking analysis. This study suggests that the selected furanocoumarins can be further investigated and evaluated for breast cancer treatment and management strategies.
Key Findings
1
In-vitro antagonist and inhibition assays for ERα, EGFR, and mTOR validated the molecular docking results.
2
Lipinski’s rule of five was applied to assess the drug-likeness of the selected furanocoumarins.
3
The findings support further investigation of selected furanocoumarins as potential agents for breast cancer treatment and management.
4
The study docked 23 furanocoumarin compounds against ERα, PR, EGFR, and mTOR to evaluate potential multitargeted anticancer activity.
5
Xanthotoxol achieved the best docking score, followed by Bergapten, Angelicin, Psoralen, and Isoimperatorin.
Research Object
Selected furanocoumarin phytochemicals interacting with breast-cancer-associated targets ERα, PR, EGFR, and mTOR
Research Subject
The binding affinity, drug-likeness, and inhibitory/antagonist activity of selected furanocoumarins against ERα, PR, EGFR, and mTOR
Publication Details
Publication Date
2019-10-31
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest